MedTrace Logo

The CANabidiol Use for RElief of Short Term Insomnia

NCT05253417 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2023-08-16

No results posted yet for this study

Summary

This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.

Conditions

  • Sleep Disturbance
  • Insomnia
  • Insomnia Type; Sleep Disorder
  • Insomnia, Transient
  • Insomnia Due to Anxiety and Fear
  • Insomnia Due to Other Mental Disorder

Interventions

DRUG

50 mg Cannabidiol (CBD)

For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.

DRUG

Placebo

Participants take four (4) placebo capsules.

DRUG

100 mg Cannabidiol (CBD)

For the study arm, '100 mg CBD' participants take four (4) CBD capsules.

Sponsors & Collaborators

  • Woolcock Institute of Medical Research

    collaborator OTHER

  • Bod Australia

    lead INDUSTRY

Principal Investigators

  • Ron Grunstein · Woolcock Institute of Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-07-07
Completion
2023-07-07

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05253417 on ClinicalTrials.gov